In vivo evaluation of the efficacy of combined albedazole-IFN-α treatment for cystic echinococcosis in mice
详细信息 查看全文
- 作者：Shengbin Zhang ; Yongsheng Zhou ; Lifu Su ; Xiaodong Zhang ; Hao Wang…
- 关键词：KeywordCystic echinococcosis (CE) ; Albendazole ; IFN ; α ; Il ; 10 ; Ultrastructural modification
- 刊名：Parasitology Research
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：116
- 期：2
- 页码：735-742
- 全文大小：
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Medical Microbiology; Microbiology; Immunology;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-1955
- 卷排序：116
文摘
Cystic echinococcosis (CE) is a serious helminthic zoonosis caused by Echinococcus granulosus metacestode worldwide. The current chemotherapy of CE is mainly based on albendazole (ABZ). However, more than 20% CE cases failed to such chemotherapy. Thus, novel and more efficient treatment options are urgently needed. This study was to evaluate the in vivo efficacy of combined ABZ-interferon (IFN)-α treatment for CE in mice. After 5 months of secondary infection with protoscoleces, mice were randomly allocated into four groups: ABZ-treated group, IFN-α-treated group, ABZ+IFN-α group, and untreated control group. Drugs in diverse treated groups were respectively administered for 2 months. Mice were then euthanized and associated indications were investigated to evaluate the therapeutic efficacy. ABZ+IFN-α induced a significant reduction of the number, size, as well as weight of cysts, compared with that in the ABZ (p < 0.05) or untreated group (p < 0.01), respectively. This effect was associated with ultrastructural modification of the cyst in the ABZ+IFN-α group. Interestingly, significant decrease of IL (interleukin)-10 in serum and in vitro production by spleen cells with ABZ+IFN-α treatment was observed in comparison with untreated control (p < 0.01). Serum IgE, IgG, and subsets were respectively decreased in ABZ+IFN-α treatment, compared with that in the control group (p < 0.01). In conclusion, our findings demonstrated that combination of ABZ with IFN-α may contribute to an efficient therapeutic regimen of human and animal CE.